STAT

As Atul Gawande steps into a risky health CEO role, here are five challenges he faces

Dr. Atul Gawande will step out of health care’s limelight on Monday to put himself under its microscope.

Taking the helm of the new health venture funded by Amazon, JPMorgan Chase, and Berkshire Hathaway is the riskiest move of his career — one that will subject his acclaimed New Yorker narratives to a real-world stress test whose outcome is far from certain.

In the balance will hang not just his reputation as a physician and writer, but perhaps the highest-profile effort to date to leverage the private sector to fix America’s fragmented and dysfunctional health care system. Gawande has made a name for himself by proposing novel solutions to the system’s many shortcomings — from surgical checklists to rooting out unnecessary care — and testing them in specific hospitals or markets around the world.

“All the eyes of American health care will be on this new initiative,” said Andrew Dreyfus, chief executive of Blue Cross Blue Shield of Massachusetts and an acquaintance of Gawande’s. “Atul understands this is high stakes, and I think that’s why he took the job.”

After interviews with leaders across the world of health care, STAT has identified five challenges Gawande

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min readIntelligence (AI) & Semantics
STAT+: Q&A: Defining Responsible AI In Health Care, With CHAI CEO Brian Anderson
CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.
STAT1 min read
STAT+: Oncologists Turn To Blood Test For Circulating Tumor DNA, But Questions Remain On How To Use The Data
A blood test known as a ctDNA test can be a good indicator of whether someone's cancer will return after surgery. But the test doesn't always clarify the next step…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Merck Pneumococcal Shot, Kansas Suing Pfizer, And More
In today's Pharmalittle roundup, we're reading about a Merck pneumococcal shot, Kansas suing Pfizer, and more.

Related Books & Audiobooks